This study provides significant data supporting the in vitro efficacy of multiple doses of iron oxide nanoparticles conjugated with ligand CD80 and VEGF antibody as a targeted drug delivery system on murine OSA cell line proliferation, supporting our hypothesis. This evidence concerns the gene CD80 and obstructive sleep apnea syndrome.